Analyst firms · Raymond James · BMRN
Raymond James BMRN price target and rating history
BioMarin Pharmaceutical Inc. (BMRN) · Health Care
Raymond James rates BioMarin Pharmaceutical Inc. (BMRN) Strong Buy with a $109 price target, as of its latest action on Oct 12, 2026. It has published 4 rating actions on BMRN since September 2023, including 1 upgrade and 0 downgrades. Across 9 firms with a BMRN price target in the last 12 months, the median target is $88. Raymond James's $109 is 24% above that.
- Current rating
- Strong Buy
- Price target
- $109
- Median target, all firms
- $88
- Actions on BMRN
- 4
Raymond James price target on BMRN
Every Raymond James rating on BMRN
- Oct 12, 2026
- Sep 3, 2025
- Oct 10, 2024
- Sep 28, 2023
How other firms rate BMRN
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| UBS | Buy | $88 | Oct 15, 2026 |
| Raymond James | Strong Buy | $109 | Oct 12, 2026 |
| BMO Capital Markets | Outperform | $98 | Aug 19, 2026 |
| Citigroup | Buy | $75 | May 19, 2026 |
| Goldman Sachs | Neutral | $69 | May 11, 2026 |
| Morgan Stanley | Overweight | $120 | Apr 27, 2026 |
| Barclays | Overweight | $80 | Jan 28, 2026 |
| Canaccord Genuity | Buy | $98 | Jan 20, 2026 |
| Leerink Partners | Market Perform | $60 | Dec 3, 2025 |
Questions about Raymond James and BMRN
- What is Raymond James's price target for BMRN?
- Raymond James's latest stated price target for BioMarin Pharmaceutical Inc. (BMRN) is $109, from its action on Oct 12, 2026.
- What is Raymond James's rating on BMRN?
- Raymond James rates BMRN Strong Buy, a bullish rating, as of Oct 12, 2026.
- When did Raymond James last change its view on BMRN?
- On Oct 12, 2026, Raymond James upgrades to Strong Buy from Outperform, price target $109.
- How does Raymond James's BMRN target compare with other analysts?
- Across 9 firms with a BMRN price target in the last 12 months, the median target is $88. Raymond James's $109 is 24% above that.
More BMRN rating histories
All Raymond James ratingsBMRN news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.